Recent studies have described a correlation between PD‐L1 expression and an improved response to PD‐1 blockade in patients with multiple types of cancer.22, 23 PD‐L1 expression is also considered a hallmark of EBV‐associated LPDs, including EBV+ plasmablastic lymphoma, EBV+ post‐transplant LPDs, and EBV+ DLBCL‐NOS.12, 17, 25 This frequent upregulation of PD‐L1 in EBV+ lymphoma patients has been the focus in the era of checkpoint inhibition. This evidence concerns the gene CD274 and lymphoma.